Cited 5 times in
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노재경 | - |
dc.date.accessioned | 2023-08-09T02:39:04Z | - |
dc.date.available | 2023-08-09T02:39:04Z | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 0020-7136 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195714 | - |
dc.description.abstract | Limited data are available on the efficacy of anti-IGF-1R agents in KRAS mutant colorectal cancer (CRC). We analysed the outcome of 69 chemorefractory, KRAS exon 2 mutant CRC patients who were enrolled in a double-blind, randomised, phase II/III study of irinotecan and cetuximab plus dalotuzumab 10 mg/kg once weekly (arm A), dalotuzumab 7.5 mg/kg every second week (arm B) or placebo (arm C). Objective response rate (5.6% vs. 3.1% vs. 4.8%), median progression-free survival (2.7 vs. 2.6 vs. 1.4 months) and overall survival (7.8 vs. 10.3 vs. 7.8 months) were not statistically significantly different between treatment groups. Most common grade ≥3 treatment-related toxicities included neutropenia, diarrhoea, hyperglycaemia, fatigue and dermatitis acneiform. Expression of IGF-1R, IGF-1, IGF-2 and EREG by quantitative real-time polymerase chain reaction was assessed in 351 patients from the same study with available data on KRAS exon 2 mutational status. Median cycle threshold values for all biomarkers were significantly lower (i.e., higher expression, p < 0.05) among patients with KRAS wild-type compared to those with KRAS exon 2 mutant tumours. No significant changes were found according to location of the primary tumour with only a trend towards lower expression of IGF-1 in colon compared to rectal cancers (p = 0.06). Albeit limited by the small sample size, this study does not appear to support a potential role for anti-IGF-1R agents in KRAS exon 2 mutant CRC. Data on IGF-1R, IGF-1 and IGF-2 expression here reported may be useful for patient stratification in future trials with inhibitors of the IGF pathway. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley-Liss | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antibodies, Monoclonal / therapeutic use* | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized / therapeutic use* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | Camptothecin / administration & dosage | - |
dc.subject.MESH | Camptothecin / analogs & derivatives | - |
dc.subject.MESH | Cetuximab / administration & dosage | - |
dc.subject.MESH | Colorectal Neoplasms / drug therapy* | - |
dc.subject.MESH | Colorectal Neoplasms / genetics | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Exons / genetics | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Insulin-Like Growth Factor I / genetics | - |
dc.subject.MESH | Insulin-Like Growth Factor II / genetics | - |
dc.subject.MESH | Irinotecan | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation / genetics* | - |
dc.subject.MESH | Proto-Oncogene Proteins p21(ras) / genetics* | - |
dc.subject.MESH | Receptor, IGF Type 1 / genetics | - |
dc.title | Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Francesco Sclafani | - |
dc.contributor.googleauthor | Tae Y Kim | - |
dc.contributor.googleauthor | David Cunningham | - |
dc.contributor.googleauthor | Tae W Kim | - |
dc.contributor.googleauthor | Josep Tabernero | - |
dc.contributor.googleauthor | Hans J Schmoll | - |
dc.contributor.googleauthor | Jae K Roh | - |
dc.contributor.googleauthor | Sun Y Kim | - |
dc.contributor.googleauthor | Young S Park | - |
dc.contributor.googleauthor | Tormod K Guren | - |
dc.contributor.googleauthor | Eliza Hawkes | - |
dc.contributor.googleauthor | Stephen J Clarke | - |
dc.contributor.googleauthor | David Ferry | - |
dc.contributor.googleauthor | Jan-Erik Frodin | - |
dc.contributor.googleauthor | Mark Ayers | - |
dc.contributor.googleauthor | Michael Nebozhyn | - |
dc.contributor.googleauthor | Clare Peckitt | - |
dc.contributor.googleauthor | Andrey Loboda | - |
dc.contributor.googleauthor | David J Watkins | - |
dc.identifier.doi | 10.1002/ijc.30453 | - |
dc.contributor.localId | A01290 | - |
dc.relation.journalcode | J01092 | - |
dc.identifier.eissn | 1097-0215 | - |
dc.identifier.pmid | 27681944 | - |
dc.subject.keyword | EREG | - |
dc.subject.keyword | IGF-1 | - |
dc.subject.keyword | IGF-1R | - |
dc.subject.keyword | IGF-2 | - |
dc.subject.keyword | KRAS exon 2 mutation | - |
dc.subject.keyword | cetuximab | - |
dc.subject.keyword | chemorefractory colorectal cancer | - |
dc.subject.keyword | dalotuzumab | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | 노재경 | - |
dc.citation.volume | 140 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 431 | - |
dc.citation.endPage | 439 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CANCER, Vol.140(2) : 431-439, 2017-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.